Revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
ELI LILLY & Co (LLY)
Price$1,143.12Cached quote
Net income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B | $22.32B | $21.49B | $19.97B | $21.22B | $19.96B | $19.62B | $23.11B | $22.60B | $24.29B | $23.08B | $21.84B | $20.37B | $18.63B |
| Gross profit | $54.13B | $36.63B | $27.04B | $21.91B | $21.01B | $19.06B | $17.60B | $16.81B | $15.53B | $15.51B | $14.92B | $14.68B | $18.20B | $17.81B | $19.22B | $18.71B | $17.59B | $16.00B | $14.38B |
| Gross margin | 83.04% | 81.31% | 79.25% | 76.77% | 74.18% | 77.66% | 78.85% | 78.22% | 77.73% | 73.09% | 74.76% | 74.85% | 78.76% | 78.78% | 79.13% | 81.08% | 80.55% | 78.52% | 77.20% |
| Research & development | $13.34B | $10.99B | $9.31B | $7.19B | $6.93B | $5.98B | $5.59B | $5.05B | $5.10B | $5.31B | $4.80B | $4.73B | $5.53B | $5.28B | $5.02B | $4.88B | $4.33B | $3.84B | $3.49B |
| Operating expenses | $27.82B | $23.73B | $20.59B | $14.78B | $14.65B | $13.00B | $12.62B | $13.28B | $13.52B | $12.25B | $12.23B | $12.02B | $12.83B | $13.07B | $13.69B | $12.18B | $12.00B | $17.33B | — |
| Operating income | $26.30B | $12.90B | $6.46B | $7.13B | $6.36B | $6.06B | $4.97B | $3.53B | $2.00B | $3.26B | $2.69B | $2.66B | $5.37B | $4.73B | $5.53B | $6.53B | $5.59B | −$1.33B | — |
| Operating margin | 40.35% | 28.64% | 18.92% | 24.97% | 22.45% | 24.69% | 22.29% | 16.44% | 10.03% | 15.37% | 13.47% | 13.56% | 23.24% | 20.94% | 22.76% | 28.30% | 25.59% | −6.55% | — |
| EBITDA | $28.30B | $14.67B | $7.98B | $8.65B | $7.90B | $7.38B | $6.21B | $5.14B | $3.57B | $4.76B | $4.12B | $4.04B | $6.82B | $6.20B | $6.90B | $7.86B | $6.89B | −$211.1M | — |
| EBITDA margin | 43.42% | 32.56% | 23.40% | 30.31% | 27.91% | 30.08% | 27.81% | 23.93% | 17.88% | 22.42% | 20.63% | 20.59% | 29.49% | 27.41% | 28.42% | 34.05% | 31.53% | −1.04% | — |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B | $3.23B | −$204.1M | $2.74B | $2.41B | $2.39B | $4.68B | $4.09B | $4.35B | $5.07B | $4.33B | −$2.07B | $2.95B |
| Net profit margin | 31.67% | 23.51% | 15.36% | 21.88% | 19.71% | 25.24% | 37.27% | 15.04% | −1.02% | 12.90% | 12.07% | 12.19% | 20.27% | 18.09% | 17.90% | 21.97% | 19.82% | −10.17% | 15.85% |
| Basic EPSper basic share | $23.00 | $11.76 | $5.82 | $6.93 | $6.15 | $6.82 | $8.93 | $3.14 | -$0.19 | $2.59 | $2.27 | $2.23 | $4.33 | $3.67 | $3.90 | $4.58 | $3.94 | -$1.89 | — |
| Diluted EPSper diluted share | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 | $6.79 | $8.89 | $3.13 | -$0.19 | $2.58 | $2.26 | $2.23 | $4.32 | $3.66 | $3.90 | $4.58 | $3.94 | -$1.89 | — |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
LILLY ENDOWMENT INC | 90.38M |
BlackRock, Inc. | 67.54M |
VANGUARD CAPITAL MANAGEMENT LLC | 53.53M |
PNC Financial Services Group, Inc. | 51.32M |
STATE STREET CORP | 36.22M |
FMR LLC | 28.46M |
Capital Research Global Investors | 20.87M |
VANGUARD PORTFOLIO MANAGEMENT LLC | 20.86M |
GEODE CAPITAL MANAGEMENT, LLC | 20.31M |
MORGAN STANLEY | 16.23M |
Capital World Investors | 15.9M |
PRICE T ROWE ASSOCIATES INC /MD/ | 13.91M |
JPMORGAN CHASE & CO | 12.6M |
NORGES BANK | 11.47M |
BANK OF AMERICA CORP /DE/ | 11.27M |
WELLINGTON MANAGEMENT GROUP LLP | 11M |
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | 10.76M |
PRIMECAP MANAGEMENT CO/CA/ | 9.17M |
NORTHERN TRUST CORP | 8.8M |
GOLDMAN SACHS GROUP INC | 7.65M |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 10, 2026Form 4 · 10b5-1 | Yuffa IlyaEVP&Pres, LLY USA&Global Capab | SellCommon Stock | 2.5K | $1.2K | $2.88M | 29.8K |
| May 6, 2026Form 4 | LILLY ENDOWMENT INCOther | SellCommon Stock | 2.2K | $996.18 | $2.20M | 91.88M |
| May 6, 2026Form 4 | LILLY ENDOWMENT INCOther | SellCommon Stock | 13.6K | $995.23 | $13.56M | 91.88M |
| Jan 7, 2026Form 4 | LILLY ENDOWMENT INCTenPercentOwner | SellCommon Stock | 2.7K | $1.1K | $3.06M | 91.90M |
| Jan 7, 2026Form 4 | LILLY ENDOWMENT INCTenPercentOwner | SellCommon Stock | 2.2K | $1.1K | $2.47M | 91.90M |
Community posts
Lilly’s obesity combination improves weight loss but raises discontinuation rates
Lilly ($LLY) reported that its experimental EloraTZP combination produced average weight loss of up to 23.3% over 48 weeks in a 367-person study involving overweight or obese adults with type 2 diabetes. The highest-dose combination of elor ...
Lilly seeks eczema label update after hand-and-foot study meets endpoints
Lilly ($LLY) said EBGLYSS achieved clear or almost clear hands and feet in 53% of treated patients after 16 weeks, compared with 27% on placebo, in the randomized ADtouch study. The 221-patient trial included adults and adolescents with mod ...
Lilly wins US approval for once-weekly insulin Onswik
Eli Lilly ($LLY) received FDA approval for Onswik, its once-weekly basal insulin for adults with type 2 diabetes, used alongside diet and exercise. The decision gives the company a less frequently administered alternative to daily basal ins ...
